OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Circulating Tumor DNA in Lymphoma	73
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	38
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	36
Future Directions in Chronic Phase CML Treatment	35
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications	26
IDH Inhibitors in AML—Promise and Pitfalls	22
Monoclonal Gammopathy-Associated Neuropathy	20
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	19
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	18
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management	16
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?	16
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	16
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	15
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	12
A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment	12
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions	12
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	12
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	11
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	11
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments	11
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	10
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	10
Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection	10
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders	10
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	10

Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	9
Blinatumomab in Practice	9
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	9
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	9
BTK Inhibitors in Chronic Lymphocytic Leukemia	8
Progress in the Management of Smoldering Multiple Myeloma	8
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities	8
Management of Chronic Myeloid Leukemia in Children and Young Adults	7
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center	7
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	7
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	7
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis	7
Central Nervous System Relapse in T and NK cell Lymphomas	7
Challenges in Chronic Myeloid Leukemia Management in South America	6
Treatment of Richter’s Transformation with Novel Therapies	6
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	6
Value in Myeloma Care: Myth or Reality	6
The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition	6
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia	6
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions	6
Treatment-Free Remission: the New Goal in CML Therapy	6
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies	6
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	6
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	5
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding	5
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	5
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma	5
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	5
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	5
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job	4
Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis — Chronic Myelomonocytic Leukemia and Beyond	4
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms	4
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	4
Real-world Management of CML: Outcomes and Treatment Patterns	4
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)	4
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities	4
Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials	4
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries	4
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies	4
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	3
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	3
Molecular Pathogenesis of Myeloproliferative Neoplasms	3
Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia	3
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms	3
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms	3
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies	3